Valar Labs

.@DCVC-backed @valarlabs is launching Vitara, a new AI-derived test that uses routine pathology slides to help oncologists choose between FOLFIRINOX and gemcitabine/nab-paclitaxel in pancreatic cancer. In validation data, patients matched to the predicted regimen lived ~3 months longer. More from @DCVC GP @hardimanjames in 🧵

Press Release: businesswire.com/news/home/2026…..

By bringing precision medicine to standard-of-care therapies, we are making personalized treatment accessible to a significantly broader patient population. This empowers oncologists to optimize commonly used regimens from day one. Validated with data from @PanCAN's Know Your Tumor registry and the COMPASS trial, the biomarker is now available for early access as Vitara Pancreas ChemoPredict.

We are thrilled to announce that the @JCO_ASCO has published our pivotal study validating our AI platform to predict response to first-line chemotherapy in advanced pancreatic cancer by analyzing standard pathology slides. Article: ascopubs.org/doi/10.1200/JC… @DrHendifar @PancPathologist @PanCAN

AI & digital pathology are reshaping cancer care — as highlighted at #ESMO25. Excited to partner with @ValarLabs on an #AI biomarker project analyzing biopsy slides from #KRAS-mutated #PancreaticCancer, advancing precision oncology. #AIinOncology dailyreporter.esmo.org/esmo-congress-…

Prognostic Performance of a CHAI Biomarker in MIBC @urotoday #SUO25 @valarlabs ☀️89 MIBC pts undergoing RC w/o NAC: CHAI 35% HR, 65% LR ☀️HR vs LR: - RFS: HR 3.64, 95% CI 1.17, 11.3 - CSS: HR 4.51, 95% CI 1.12, 18.1 - OS: HR 3.51, 95% CI 1.24, 9.95

We are pleased to partner with @PathNetLab to expand access to Vesta Bladder tests to large urology practices nationally Press Release: businesswire.com/news/home/2025…

Great work done @UroCancerMD @UrogerliMD @SpiessPhilippe @BrynLauner @VikramNarayan @siadaneshmand @bkonety to validate the CHAI (Computational Histology Artificial Intelligence) model for risk stratification of patients with Ta HG #NMIBC in a multicenter cohort: ☑️CHAI outperformed EAU and AUA risk models in HG-Recurrence-Free Survival and Progression Free Survival ☑️CHAI shows a great potential of AI-powered pathology to refine risk assessment Curious to see future performance also in other settings including LG IR NMIBC #BladderCancer #Artificial_Intelligence @EUplatinum @oncodaily @urotoday 👉sciencedirect.com/science/articl…

Honored to contribute and usher in an era of AI-driven precision in global bladder cancer care. Computational histology transforming risk stratification and outcomes. 🌎👍💫 @UTMBUrology @utmbhealth @UTMBPresident @UTMBPathRes @valarlabs @IBCG_BladderCA @AmerUrological @Uroweb

Wonderful collaboration with @UroCancerMD @siadaneshmand to demonstrate the external validation performance of CHAI biomarkers to prognostic risk of recurrence and progression in bladder cancer

🔍 New in European Urology Computational histology AI improves risk stratification in high-grade Ta NMIBC In a multicenter cohort, the Computational Histology Artificial Intelligence (CHAI) assay outperformed current EAU and AUA risk models in predicting recurrence and progression after BCG. These findings highlight the potential of AI-powered pathology to refine risk assessment in non–muscle-invasive bladder cancer. 📄 Chang SS et al. Eur Urol. 2025;88:411–413. 🔗 buff.ly/MjMlYXB #EuropeanUrology #BladderCancer #ArtificialIntelligence #Urology #Pathology #PrecisionOncology #BCG #EAUguidelines #AUA #DigitalPathology #ClinicalResearch #AIinMedicine

We are pleased to announce our partnership with @LumeaDigital to streamline access to precision medicine for all bladder cancer patients. Vesta Bladder BCGPredict and Vesta Bladder Risk Stratify are first of their kind AI diagnostic tests to aid with treatment selection and prognostication in non muscle invasive bladder cancer. einpresswire.com/article/856224…

Publication: euoncology.europeanurology.com/article/S2588-…

Listen to an engaging conversation hosted by @urotoday between two leaders in bladder cancer @UroCancerMD and @VigneshPackiam on our data in @EurUrolOncol using Vesta BCGPredict to analyze patient outcomes between BCG vs Gem/Doce Interview: urotoday.com/video-lectures… Big thank you to all collaborators involved! @pjhensley11 @UroDocAsh @saumyg

Publication: authors.elsevier.com/c/1lFoD14kpm0h…

We are pleased to share our new publication in European Urology validating Vesta Risk Stratify biomarkers for prediction of recurrence and progression in High Grade Ta Bladder Cancer. Press Release: businesswire.com/news/home/2025… Grateful to all the collaborators involved and @UroCancerMD and @siadaneshmand for their leadership on this work. @UroDocAsh @VigneshPackiam @YairLotan @pjhensley11 @VikramNarayan @SWilliams_MD @UrogerliMD @SpiessPhilippe @marigfern @BrynLauner @dhpatil101 @bkonety @IBCG_BladderCA @anirrjoshi @VisweshKrishna @tjroycemd

Excited to share our @valarlabs publication in @EUplatinum validating Vesta Risk Stratify computational histology AI biomarkers to predict recurrence and progression in High Grade Ta Bladder Cancer. (1/5) Publication: authors.elsevier.com/c/1lFoD14kpm0h…

Comprehensive breakdown of our recent @EurUrolOncol publication

Our recent publication in @EurUrolOncol demonstrates - for the first time -that an AI-powered histologic biomarker (CHAI) can predict response to intravesical BCG vs. gemcitabine/docetaxel in high-grade NMIBC. A critical step forward in precision intravesical therapy. doi.org/10.1016/j.euo.… 🧵1/6

An #ArtificialIntelligence-powered predictive biomarker for response to intravesical BCG versus gemcitabine-docetaxel for high-grade #NMIBC. Presentation by @VigneshPackiam @RutgersCancer. #AUA25 written coverage by @RKSayyid @USC > bit.ly/4jQSrbg @AmerUrological